Contributions
Abstract: PB1761
Type: Publication Only
Background
Information about the second tumors that arise after recovery from BNHL is not so extensive. Information about the second tumor after BNHL with HCV is scarce.
Aims
The purpose of our study was to study which secondary tumors, with what frequency and at what time develop in these groups of patients.
The study included patients with BNHL treated from 2001 to 2017.The first group was patients with BNHL+HCV, there were 213. In the second group was patients with BNHL without HCV there were 835. The median age was in the first group - 48 years, in the second group - 60 years. The ratio of men and women in the first group was 1: 1, in the second 1: 2.5
Methods
During the observation in the first group, the second tumors developed in 23 patients (11%), in the second group - in 18 patients (2%). In the first group of the onset of the second tumor ranged from 16 to 96 months, the median was 44 months after the end of treatment BNHL. In the second group, the second tumor occurred from 47 to 144 months, the median was 60 months.
Results
During the observation in the first group, the second tumors developed in 23 patients (11%), in the second group - in 18 patients (2%). In the first group of the onset of the second tumor ranged from 16 to 96 months, the median was 44 months after the end of treatment BNHL. In the second group, the second tumor occurred from 47 to 144 months, the median was 60 months.
In the first group, 5 of 23 patients developed MDS / AML. Another 17 patients developed solid tumors. Among the solid tumors were 3 primary liver cancer, 5 renal cancer , 5 colon cancer. According to one type of cancer, the following occurred: uterine body cancer, brain tumor, soft tissue sarcoma, lung cancer, breast cancer. In all patients during the diagnosis of lymphoma, the viral load was high. The median viral load was 2.7x106 copies / ml. The genotype of hepatitis C was determined in 18 of 23 patients. The genotype 1b was in 14 of 18 patients, 2 genotype in 2 patients, and the 3 genotype was in 2 patients. Of the 23 cases, the second tumors were diagnosed in 18 patients who did not receive antiviral therapy and only 5 patients who received antiviral therapy with interferon + ribavirin. All patients who developed MDS / AML received only polychemotherapy. In the first group with IHC, the study of the expression of HCV proteins was carried out in 13 cases. Expression of HCV proteins was detected in 6 cases: liver cancer - 3, kidney cancer - 3.
In the second group of patients, of the 18 second tumors were breast cancer-3 patients, uterine body cancer-4 patients, thyroid cancer was in 2 patients. In one case: stomach cancer, colon cancer, prostate cancer, melanoma, kidney cancer, laryngeal cancer, hepatocellular cancer, lung cancer, skin cancer were identified.
Conclusion
When comparing these two groups of patients with BNHL + HCV and BNHL without HCV, the frequency of diagnosis of the second tumor was higher than in the BNHL group - 11% versus 2%. The first group of patients was younger, the second tumors occurred earlier than 44 months compared to 60 months. In patients receiving antiviral therapy, the second tumor was diagnosed reliably less frequently than in a group of patients who did not receive antiviral therapy. HCV is an additional risk factor for developing second tumors.
Session topic: 21. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): Hepatitis C virus, Non-Hodgkin's lymphoma, Second malignancy
Abstract: PB1761
Type: Publication Only
Background
Information about the second tumors that arise after recovery from BNHL is not so extensive. Information about the second tumor after BNHL with HCV is scarce.
Aims
The purpose of our study was to study which secondary tumors, with what frequency and at what time develop in these groups of patients.
The study included patients with BNHL treated from 2001 to 2017.The first group was patients with BNHL+HCV, there were 213. In the second group was patients with BNHL without HCV there were 835. The median age was in the first group - 48 years, in the second group - 60 years. The ratio of men and women in the first group was 1: 1, in the second 1: 2.5
Methods
During the observation in the first group, the second tumors developed in 23 patients (11%), in the second group - in 18 patients (2%). In the first group of the onset of the second tumor ranged from 16 to 96 months, the median was 44 months after the end of treatment BNHL. In the second group, the second tumor occurred from 47 to 144 months, the median was 60 months.
Results
During the observation in the first group, the second tumors developed in 23 patients (11%), in the second group - in 18 patients (2%). In the first group of the onset of the second tumor ranged from 16 to 96 months, the median was 44 months after the end of treatment BNHL. In the second group, the second tumor occurred from 47 to 144 months, the median was 60 months.
In the first group, 5 of 23 patients developed MDS / AML. Another 17 patients developed solid tumors. Among the solid tumors were 3 primary liver cancer, 5 renal cancer , 5 colon cancer. According to one type of cancer, the following occurred: uterine body cancer, brain tumor, soft tissue sarcoma, lung cancer, breast cancer. In all patients during the diagnosis of lymphoma, the viral load was high. The median viral load was 2.7x106 copies / ml. The genotype of hepatitis C was determined in 18 of 23 patients. The genotype 1b was in 14 of 18 patients, 2 genotype in 2 patients, and the 3 genotype was in 2 patients. Of the 23 cases, the second tumors were diagnosed in 18 patients who did not receive antiviral therapy and only 5 patients who received antiviral therapy with interferon + ribavirin. All patients who developed MDS / AML received only polychemotherapy. In the first group with IHC, the study of the expression of HCV proteins was carried out in 13 cases. Expression of HCV proteins was detected in 6 cases: liver cancer - 3, kidney cancer - 3.
In the second group of patients, of the 18 second tumors were breast cancer-3 patients, uterine body cancer-4 patients, thyroid cancer was in 2 patients. In one case: stomach cancer, colon cancer, prostate cancer, melanoma, kidney cancer, laryngeal cancer, hepatocellular cancer, lung cancer, skin cancer were identified.
Conclusion
When comparing these two groups of patients with BNHL + HCV and BNHL without HCV, the frequency of diagnosis of the second tumor was higher than in the BNHL group - 11% versus 2%. The first group of patients was younger, the second tumors occurred earlier than 44 months compared to 60 months. In patients receiving antiviral therapy, the second tumor was diagnosed reliably less frequently than in a group of patients who did not receive antiviral therapy. HCV is an additional risk factor for developing second tumors.
Session topic: 21. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): Hepatitis C virus, Non-Hodgkin's lymphoma, Second malignancy